Article
Cytogen Corp. and Matritech, Inc., offer the NMP22 BladderChek point-of-caretest for bladder cancer, which is now approved for detecting the disease.The product had been previously approved for monitoring patients who hadalready been diagnosed with bladder cancer.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.